Following the discovery that CF epithelial function could be rescued by a small molecule in vitro (8), VX-770 or ivacaftor emerged as the first clinically approved potentiator therapy for CF—a drug that increases the open probability (Po) of CFTR. This evidence concerns the gene CFTR and cystic fibrosis.